Leadership

Accomplished operators and drug developers converting platform science into clinical ambition at ARTAN.

Anthony Schwartz, Ph.D.

Co-Founder & Chief Operating Officer

Anthony Schwartz, Ph.D. is a serial biotech founder and operator with nearly two decades of experience building and leading companies across oncology, rare disease, and longevity. A bioengineer by training (Ph.D.; NIH/NCI postdoctoral fellow), he is also a Johns Hopkins University faculty member. Over his career he has been part of over 20 startups and held founder, CEO, and operating roles at numerous biotechnology companies and venture funds, helping to secure major financings and advance assets to FDA approval. He co-founded ARTAN Bio and serves as its Chief Operating Officer, driving operations and execution as the platform advances toward the clinic.

Michael Torres, Ph.D.

Co-Founder & Chief Scientific Officer

Michael is a serial biotech entrepreneur and drug developer. He co-founded ReCode Therapeutics, the clinical-stage genetic-medicines company built on the SORT lipid-nanoparticle delivery platform (raising more than $450M), and went on to found and lead CrossBridge Bio, advancing a next-generation dual-payload antibody-drug conjugate from a university license to a $300M acquisition by Eli Lilly in under three years on roughly $10M raised. He co-founded ARTAN Bio and serves as Chief Scientific Officer and is the lead investor in the company’s seed round.

Brian Bodemann, Ph.D.

Chief Executive Officer

Brian earned his Ph.D. in pharmacology at UT Southwestern Medical Center and completed a postdoctoral fellowship at the university’s NCI-designated cancer center, giving him a research-grade command of the science that he pairs with broad experience across life-science commercial markets. As Chief Executive Officer, he leads ARTAN Bio’s translation from discovery toward the clinic, working alongside co-founders Michael Torres and Anthony Schwartz to connect the platform’s biology to the indications, partners, and markets it can serve.

From conviction to a signal, and toward the clinic.

Community backs the idea
Early support gathered behind ARTAN-102, conviction in translation rescue before the data existed.
First in vivo signal
ARTAN-102 detected across major organs, including the brain, in preclinical animal models.
Building momentum
Assembling the pieces that turn a signal into a program: manufacturing, science, and partners.
Toward the clinic
A deliberate path: toxicology, then IND-enabling work, then first-in-human.

Science first. Community-backed. Company-executed.

VitaDAO

Early funding and DeSci ecosystem network.

BIO

DeSci network for biotech company formation.

Molecule

On-chain research IP infrastructure.

Syenex

Delivery partner for Artan-201, hematopoietic stem cells.

spARK Labs by ARK Invest

Building at the ARK Invest innovation hub in St. Petersburg, FL.

Open partners

News and milestones from ARTAN Bio.

June 4, 2026 · St. Petersburg, Fla.

ARTAN Bio Raises $200,000 in Decentralized Funding to Advance Longevity Science Through Mutation-Specific Codon Suppression

ARTAN Bio announced a $200,000 seed raise to fund preclinical advancement of its codon suppressor platform targeting nonsense mutations.

July 1, 2026 · St. Petersburg, Fla.

ARTAN Bio Closes $1 Million Seed Round to Advance its Codon Suppressor Platform Toward Human Studies

ARTAN Bio closed a $1 million seed round led by co-founder Michael Torres, Ph.D., and appointed Brian Bodemann as Chief Executive Officer to advance the codon suppressor platform toward human studies.